Frontlight ResearchEarly access
TerminatedPhase 1
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Key facts
- Who runs it
- Novartis Pharmaceuticals
- Where
- Israel, Netherlands, Spain, and Switzerland5 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 24 people enrolled
- Started
- 6 Oct 2023
- Ended
- 13 Dec 2024
- Type of study
- Interventional
- Treatments tested
- 68Ga-FF58
- 177Lu-FF58
- Record updated
- 24 December 2025
- Why it stopped
- The decision was not based on any safety concerns
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Age >= 18 years old
- Patients with locally advanced unresectable or metastatic PDAC, locally advanced unresectable or metastatic GEA, or recurrent GBM
- To be treated with [177Lu]Lu-FF58, patients must have at least one measurable lesion that shows [68Ga]Ga-FF58 uptake on PET/CT or PET/MRI
Who cannot take part
- Prior external beam radiation therapy (EBRT) to > 25% of the bone marrow
- Non-GBM patients: Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within 1 week before [177Lu]Lu-FF58 administration; Other protocol-defined inclusion/exclusion criteria may apply
- Absolute neutrophil count (ANC) < 1.5 x 109/L, hemoglobin < 10 g/dL, or platelet count < 100 x 109/L
- Creatinine clearance < 60 mL/min
- Unmanageable bladder outflow obstruction or urinary incontinence
This trial has no sites in United States.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of the study is to test the safety and dosing of [177Lu]Lu-FF58, a radioligand therapy for patients with advanced or metastatic tumors that express proteins known as integrins: alpha-v beta-3 integrin (αvβ3) and alpha-v beta-5 integrin (αvβ5). The study will also further characterize the radioligand imaging agent [68Ga]Ga-FF58 including its ability to identify tumor lesions and its safety profile.
The group in the trial
- Arm 1Treatment being tested
Patients will receive 68Ga-FF58 and only patients with tumor uptake of 68Ga-FF58 will receive 177Lu-FF58.
Treatment: 68Ga-FF58 and 177Lu-FF58
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors.
- Record updated
- 24 December 2025